Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and the Nuffield Department of Medicine greatly mourn the death of Professor Sir Nicholas White, a distinguished clinician and scientist who was internationally recognised as the leading figure in improving the treatment of malaria worldwide, and whose work has made a lasting contribution to global health research - saving millions of lives worldwide. Our thoughts are with his family at this time.

Nick White was Professor of Tropical Medicine at the University of Oxford and Mahidol University in Thailand. He was a central figure in the development of the Mahidol Oxford Tropical Medicine Research Unit (MORU) and its sister unit, the Oxford University Clinical Research Unit in Vietnam (OUCRU). In these endeavours he was supported by the Wellcome Trust throughout his career.

From his arrival in Thailand in 1980, he was closely involved in establishing MORU as a leading centre for clinical research on malaria and other infectious diseases, working in long-term partnership with local hospitals, clinicians, and researchers. Under his scientific leadership, MORU became world renowned for clinical research that combined methodological rigour with direct relevance to patient care.

Nick was internationally recognised as a leading expert in malaria therapeutics, making seminal contributions to the field that transformed global policy. At a time when resistance to existing antimalarial drugs threatened effective treatment, Nick led a team that generated the clinical evidence through multinational clinical trials that underpinned the widespread adoption of artemisinin drugs. He developed the theory and evidence to support artemisinin-based combination therapies, which have become the standard of care for Plasmodium falciparum malaria, and intravenous artesunate for the treatment of severe malaria. These treatments have been used in more than a billion patients and saved millions of lives. His work continues to shape clinical practice.

Nick’s scientific interests extended to other infectious diseases of major public health importance, including dengue, melioidosis, typhoid fever, and tetanus. Across these areas, his research was grounded in careful clinical observation and a consistent focus on practical solutions that had maximum impact on health outcomes. His pragmatic approach ensured that his findings were applicable in real-world settings, particularly in resource-limited environments. He made further important contributions to healthcare during the COVID-19 pandemic.

 

 

Read the full story on the Nuffield Department of Medicine website.

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.